

IN THE CLAIMS:

Kindly cancel without prejudice claims 71-91 and substitute therefor new claims 92-106.

--92. A method of expressing a Factor IX protein in the liver of a mammal, comprising:

administering recombinant adeno-associated virus (rAAV) particles to mammalian liver cells to yield liver cells expressing Factor IX protein following infection of said mammalian liver cells, wherein said rAAV comprises a polynucleotide encoding Factor IX under control of a liver specific promoter, enhancer, or promoter and enhancer.

93. The method of claim 92, wherein said administering comprises injecting said rAAV into the portal vasculature of said mammal.

94. The method of claim 92, wherein said rAAV is administered to said cell ex vivo and cells expressing Factor IX are administered to said mammal.

95. The method of claim 92, wherein said rAAV comprises two adeno-associated virus (AAV) inverted terminal repeats, wherein said inverted terminal repeats flank said enhancer, promoter or both an enhancer and a promoter, and said structural gene encoding Factor IX.

96. The method of claim 92, wherein said Factor IX is diffusible and is expressed in the blood.

97. The method of claim 92, wherein said liver specific promoter or enhancer is selected from the group consisting of the albumin promoter, the afetoprotein promoter, the afetoprotein enhancer, the human apolipoprotein E (ApoE) promoter, HCR-1, HCR-2, the AI apolipoprotein liver-specific enhancer and the α 1-antitrypsin promoter.

98. A method of treating a blood disease or disorder in a mammal, comprising:

administering a therapeutically effective dosage of Factor IX-expressing recombinant adeno-associated virus (rAAV) particles to liver cells of said mammal, wherein said rAAV particles comprise a polynucleotide encoding Factor IX under control of a liver specific

AMENDMENT UNDER 37 CFR 1.111
U.S Error! Reference source not found.

promoter, enhancer, or promoter and enhancer, and said particles provide for liver-specific expression of Factor IX.

99. The method of claim 98, wherein said disorder is a coagulation defect.

100. The method of claim 98, wherein the liver specific promoter or enhancer is selected from the group consisting of the albumin promoter, the α fetoprotein promoter, the α fetoprotein enhancer, the human apolipoprotein E (ApoE) promoter, HCR-1, HCR-2, the AI apolipoprotein liver-specific enhancer and the α I-antitrypsin promoter.

101. The method of claim 98, wherein said administering further comprises injecting said rAAV into the portal vasculature of said mammal.--

Kindly cancel without prejudice claims 48 and 54.